

Special Issue

Humoral and Cellular Response after COVID-19 Vaccination

Message from the Guest Editor

COVID-19 vaccines are effective for infection outbreak control. However, waning immunity over time and the emergence of new SARS-CoV-2 variants have caused immune resistance to current vaccines. This Special Issue focuses on the long-term humoral and cellular responses after COVID-19 vaccination. We are interested in manuscripts that focus on emerging issues in COVID-19 vaccination immune response as well as factors influencing current vaccines' effectiveness. Papers identifying novel strategies for improving immune response in immunocompromised patients are also of interest. Since the long-term efficacy of COVID-19 vaccines is still unknown, we are calling for studies on both humoral and cellular long-term immunity as well as those investigating the immunity effectiveness of additional booster vaccine doses. The submission of original articles, systematic reviews, and short communications on related topics are welcome.

Guest Editor

Dr. Michal Herman-Edelstein

Department of Nephrology and Hypertension, Rabin Medical Center, Sackler School of Medicine, Tel-Aviv University, Petah Tikva, Israel

Deadline for manuscript submissions

closed (31 December 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/124354

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).